Emergingby GlyphReCode Therapeutics closes over $29M to advance inhaled mRNA therapies
The SORT LNP developer also added a Praxis collaboration on ASO delivery.
Nanotechnologyrecodetx.com
ReCode Therapeutics
StartupUS1 field
Where it works
| Technology | ||
|---|---|---|
| NanotechnologyDevelops SORT lipid nanoparticles that deliver mRNA and gene correction to specific tissues. | Develops SORT lipid nanoparticles that deliver mRNA and gene correction to specific tissues. | recodetx.com |
Events
Funding
$29M
About
- Source
- recodetx.com (official, added by seed)
- First seen
- Sep 25, 2026
- Last seen
- Oct 6, 2026
- Across Glyph
- ReCode Therapeutics on Companies
ReCode Therapeutics
Joined in Nanotechnology. Develops SORT lipid nanoparticles that deliver mRNA and gene correction to specific tissues.
ReCode Therapeutics
Added in Nanotechnology. Develops SORT lipid nanoparticles that deliver mRNA and gene correction to specific tissues.